The impact of the COVID-19 pandemic on ICU clinical trials: a description of one research team ’s experience
ConclusionsWhile the parent clinical trial remained opened, cumulative factors adversely impacted the trial during the pandemic period with fewer patients accrued. The human toll of the pandemic on research staff, clinicians, and patients/family members demands that investigators be proactive in managing these challenges to conduct ICU clinical trials successfully, including careful oversight of human and financial resources.Trial registrationClinicalTrials.gov NCT#02,819,141 Registered 29 June 2016. (Source: Trials)
Source: Trials - May 11, 2023 Category: Research Source Type: clinical trials
Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Condition: Coronavirus Interventions: Biological: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells); Biological: Recombinant novel coronavirus protein vaccine (CHO cells) Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 9, 2023 Category: Research Source Type: clinical trials
